Nuevolution has signed an agreement with Boehringer Ingelheim to screen a range of small molecules for discovering and enhancing drug candidates by using Nuevolution’s proprietary Chemetics drug discovery technology.
The drugs which will be discovered will target the diseases that interest to Boehringer.As per the terms of the agreement, Nuevolution is responsible to get an upfront payment, research funding, and milestone payments from Boehringer Ingelheim as candidate molecules progress through preclinical and clinical development and onto the market.
In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products.Further financial details were not disclosed.
Nuevolution CEO Alex Gouliaev said they are looking forward to successfully tackle further challenging targets in collaboration with the scientists at Boehringer Ingelheim.
